JP2002500667A - 人間の患者に対して経口的にタキサン類を投薬するための方法及び組成物 - Google Patents
人間の患者に対して経口的にタキサン類を投薬するための方法及び組成物Info
- Publication number
- JP2002500667A JP2002500667A JP50066399A JP50066399A JP2002500667A JP 2002500667 A JP2002500667 A JP 2002500667A JP 50066399 A JP50066399 A JP 50066399A JP 50066399 A JP50066399 A JP 50066399A JP 2002500667 A JP2002500667 A JP 2002500667A
- Authority
- JP
- Japan
- Prior art keywords
- taxane
- paclitaxel
- administered
- cyclosporin
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940123237 Taxane Drugs 0.000 title claims abstract description 100
- 238000000034 method Methods 0.000 title claims abstract description 86
- 239000000203 mixture Substances 0.000 title description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 129
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 125
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 125
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims abstract description 67
- 239000003623 enhancer Substances 0.000 claims abstract description 51
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 49
- 108010036949 Cyclosporine Proteins 0.000 claims abstract description 49
- 229960001265 ciclosporin Drugs 0.000 claims abstract description 49
- 229930105110 Cyclosporin A Natural products 0.000 claims abstract description 41
- 229930182912 cyclosporin Natural products 0.000 claims abstract description 27
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 20
- 230000009610 hypersensitivity Effects 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 76
- 229940079593 drug Drugs 0.000 claims description 72
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 24
- 229960003668 docetaxel Drugs 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 239000000651 prodrug Substances 0.000 claims description 20
- 229940002612 prodrug Drugs 0.000 claims description 20
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 11
- 108010036941 Cyclosporins Proteins 0.000 claims description 10
- 239000006186 oral dosage form Substances 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- KUSICUWKCBCAHV-ZSINMPTNSA-N [(e,1r,2r)-1-[(2s,5s,11s,14s,17s,20s,23r,26s,29s,32s)-5-ethyl-1,7,10,16,20,23,25,28,31-nonamethyl-11,17,26,29-tetrakis(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-14,32-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacont-2-y Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](OC(C)=O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O KUSICUWKCBCAHV-ZSINMPTNSA-N 0.000 claims description 7
- 108010040786 dihydrocyclosporin C Proteins 0.000 claims description 7
- GNGBSKIQPUCELM-YBAOVNABSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-[(e,2r)-2-methylhex-4-enyl]-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29, Chemical compound CC[C@@H]1NC(=O)[C@H](C[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O GNGBSKIQPUCELM-YBAOVNABSA-N 0.000 claims description 6
- GNGBSKIQPUCELM-UHFFFAOYSA-N Cyclosporin F Natural products CCC1NC(=O)C(CC(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O GNGBSKIQPUCELM-UHFFFAOYSA-N 0.000 claims description 6
- 108010019252 cyclosporin F Proteins 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- ZNVBEWJRWHNZMK-SYOLRUPNSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,2 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O ZNVBEWJRWHNZMK-SYOLRUPNSA-N 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 108010019594 cyclosporin D Proteins 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 201000004792 malaria Diseases 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 230000000451 tissue damage Effects 0.000 claims description 3
- 231100000827 tissue damage Toxicity 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000030961 allergic reaction Diseases 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 208000024558 digestive system cancer Diseases 0.000 claims description 2
- 201000010231 gastrointestinal system cancer Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- TYFOVYYNQGNDKH-HHPJSCBPSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-[(1r,2r)-1-hydroxy-2-methylhexyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23, Chemical compound CCCC[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC1=O TYFOVYYNQGNDKH-HHPJSCBPSA-N 0.000 claims 6
- 108010040764 dihydrocyclosporin A Proteins 0.000 claims 6
- JTOKYIBTLUQVQV-QRVTZXGZSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-[(1r)-1-hydroxyethyl]-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontan Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H]([C@@H](C)O)NC1=O JTOKYIBTLUQVQV-QRVTZXGZSA-N 0.000 claims 3
- JTOKYIBTLUQVQV-UHFFFAOYSA-N Cyclosporin C Natural products CC=CCC(C)C(O)C1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)O)NC1=O JTOKYIBTLUQVQV-UHFFFAOYSA-N 0.000 claims 3
- 108010019248 cyclosporin C Proteins 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 1
- 102000017033 Porins Human genes 0.000 claims 1
- 108010013381 Porins Proteins 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000009877 rendering Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 abstract description 16
- 230000001225 therapeutic effect Effects 0.000 abstract description 14
- 230000036765 blood level Effects 0.000 abstract description 12
- 238000009101 premedication Methods 0.000 abstract description 8
- 229940034982 antineoplastic agent Drugs 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 22
- 238000010521 absorption reaction Methods 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 16
- 241000282412 Homo Species 0.000 description 16
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- 238000001990 intravenous administration Methods 0.000 description 16
- 230000036470 plasma concentration Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 238000011260 co-administration Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 230000036457 multidrug resistance Effects 0.000 description 9
- 230000001506 immunosuppresive effect Effects 0.000 description 8
- 239000008389 polyethoxylated castor oil Substances 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- -1 cyclosporins A to Z Natural products 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007897 gelcap Substances 0.000 description 3
- 229940060367 inert ingredients Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229960001404 quinidine Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229940049937 Pgp inhibitor Drugs 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000000039 congener Substances 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000002748 glycoprotein P inhibitor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000007154 intracellular accumulation Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229950000688 phenothiazine Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940063122 sandimmune Drugs 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- UCOQITKXMNKTKF-MXGZYYNMSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28,30-decamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C)NC1=O UCOQITKXMNKTKF-MXGZYYNMSA-N 0.000 description 1
- 108010030583 (melle-4)cyclosporin Proteins 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Polymers FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010050017 Lung cancer metastatic Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- YJDYDFNKCBANTM-QCWCSKBGSA-N SDZ PSC 833 Chemical compound C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O YJDYDFNKCBANTM-QCWCSKBGSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- 108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- 241001116500 Taxus Species 0.000 description 1
- 241000202349 Taxus brevifolia Species 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000123975 Trichoderma polysporum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 150000004625 docetaxel anhydrous derivatives Chemical class 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000002642 intravenous therapy Methods 0.000 description 1
- 230000006122 isoprenylation Effects 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- RPJPZDVUUKWPGT-FOIHOXPVSA-N nim811 Chemical compound CC[C@H](C)[C@@H]1N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC1=O RPJPZDVUUKWPGT-FOIHOXPVSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000008008 oral excipient Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036332 sexual response Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 208000027140 splenic disease Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 108010082372 valspodar Proteins 0.000 description 1
- 229950010938 valspodar Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.タキサン応答性のある疾患状態にかかった人間の患者に対するタキサンの 経口投与であって、前記タキサンが、前記の状態を治療するのに有効な量にて投 与されることを特徴とする、タキサン応答性のある疾患状態にかかった人間の患 者に対するタキサンの経口投与。 2.パクリタクセル応答性のある疾患状態にかかった人間の患者に対するパク リタクセルの経口投与であって、前記パクリタクセルが、前記の状態を治療する のに有効な量にて投与されることを特徴とする、パクリタクセル応答性のある疾 患状態にかかった人間の患者に対するパクリタクセルの経口投与。 3.ドセタクセル応答性のある疾患状態にかかった人間の患者に対するドセタ クセルの経口投与であって、前記ドセタクセルが、前記の状態を治療するのに有 効な量にて投与されることを特徴とする、ドセタクセル応答性のある疾患状態に かかった人間の患者に対するドセタクセルの経口投与。 4.パクリタクセル又はドセタクセルの誘導体、類似物又はプロドラッグに対 して応答性のある疾患状態を治療するための、人間の患者への前記誘導体、類似 物又はプロドラッグの経口投与であって、前記誘導体、類似物又はプロドラッグ が、前記の状態を治療するのに効果的な量にて投与されることを特徴とする、人 間の患者への、パクリタクセル又はドセタクセルの誘導体、類似物又はプロドラ ッグの経口投与。 5.前記プロドラッグが、パクリタクセル−2’−MPM又はドセタクセル− 2’−MPMであることを特徴とする請求項4記載の、パクリタクセル又はドセ タクセルのプロドラッグの経口投与。 6.パクリタクセルの前記有効量が、患者の体重に基づいて約2〜30mg/ kgであることを特徴とする請求項2に記載の経口投与。 7.前記有効量が約2〜6mg/kgであることを特徴とする請求項6に記載 の経口投与。 8.パクリタクセルの前記有効量が、患者の身体の表面積に基づいて約20〜 1000mg/m2であることを特徴とする請求項2に記載の経口投与。 9.前記有効量が約50〜200mg/m2であることを特徴とする請求項8 に記載の経口投与。 10.経口的に投与されるタキサンを、タキサン応答性のある疾患状態を治療す るの充分なレベルで人間の患者に対して生物学的利用可能なものとする方法であ って、前記方法が、サイクロスポリンAないしZ、(Me−lle−4)−サイ クロスポリン、ジヒドロサイクロスポリンA、ジヒドロサイクロスポリンC、ア セチルサイクロスポリンAから成るグループより選ばれた経口生体利用率向上剤 の有効量と共に、疾患を治療するのに有効な量のタキサンを前記患者に対して経 口共投与することを含むことを特徴とする、経口的に投与されるタキサンを、人 間の患者に対して生物学的利用可能なものとする方法。 11.前記タキサンがパクリタクセルであることを特徴とする請求項10に記載 の方法。 12.前記タキサンがドセタクセルであることを特徴とする請求項10に記載の 方法。 13.前記タキサンが、パクリタクセル又はドセタクセルの誘導体、類似物又は プロドラッグであることを特徴とする請求項10に記載の方法。 14.前記タキサンが、プロドラッグであるパクリタクセル−2’−MPM又は プロドラッグであるドセタクセル−2’−MPMであることを特徴とする請求項 13に記載の方法。 15.前記の生体利用率向上剤が、サイクロスポリンA、サイクロスポリンC、 サイクロスポリンD、サイクロスポリンF、ジヒドロサイクロスポリンA、ジヒ ドロサイクロスポリンC及びアセチルサイクロスポリンAから成るグループより 選ばれたものであることを特徴とする請求項10に記載の方法。 16.約0.1〜約20mg/kgの前記向上剤が、患者の体重に基づいて投与 されることを特徴とする請求項15に記載の方法。 17.約5mg/kgの前記向上剤が投与されることを特徴とする請求項16に 記載の方法。 18.パクリタクセルの前記有効量が、患者の体重に基づいて約2〜30mg/ kgであることを特徴とする請求項11に記載の方法。 19.前記有効量が約2〜6mg/kgであることを特徴とする請求項18に記 載の方法。 20.パクリタクセルの前記有効量が、患者の身体の表面積に基づいて約20〜 1000mg/m2であることを特徴とする請求項11に記載の方法。 21.前記有効量が約50〜200mg/m2であることを特徴とする請求項2 0に記載の方法。 22.約2〜30mg/kg又は約20〜1000mg/m2のパクリタクセル が、約0.1〜20mg/kgのサイクロスポリンAと共に、前記患者に対して 共投与されることを特徴とする請求項10に記載の方法。 23.前記向上剤が、 a)前記タキサン投与の約0.5〜72時間前、 b)前記タキサン投与の0.5時間以内前、前記タキサン投与と一緒に、 又は前記タキサン投与の0.5時間以内後、又は c)前記タキサン投与の約0.5〜72時間前と、再び、0.5時間以内 前、一緒に、又は0.5時間以内後の両方、 のいずれかで投与されることを特徴とする請求項10に記載の方法。 24.前記タキサンがパクリタクセルであり、しかも前記向上剤がサイクロスポ リンAであることを特徴とする請求項23に記載の方法。 25.前記タキサンと前記向上剤がそれぞれ、個別の経口投薬形態にて投与され ることを特徴とする請求項10に記載の方法。 26.前記タキサンと前記向上剤が、混合型経口投薬形態にて一緒に投与される ことを特徴とする請求項10に記載の方法。 27.タキサン応答性のある疾患状態にかかった人間の患者を治療するための方 法であって、前記方法が、疾患を治療するのに有効な量のタキサンを前記患者に 対して経口共投与することを含むことを特徴とする、タキサン応答性のある疾患 状態にかかった人間の患者の治療方法。 28.前記タキサンがパクリタクセルであることを特徴とする請求項27に記載 の方法。 29.前記タキサンがドセタクセルであることを特徴とする請求項27に記載の 方法。 30.前記タキサンが、パクリタクセル又はドセタクセルの誘導体、類似物又は プロドラッグであることを特徴とする請求項27に記載の方法。 31.前記タキサンが、パクリタクセル−2’−MPM又はドセタクセル−2’ −MPMから成るグループより選ばれたプロドラッグであることを特徴とする請 求項30に記載の方法。 32.パクリタクセルの前記有効量が、患者の体重に基づいて約2〜30mg/ kgであることを特徴とする請求項28に記載の方法。 33.前記有効量が約2〜6mg/kgであることを特徴とする請求項32に記 載の方法。 34.パクリタクセルの前記有効量が、患者の身体の表面積に基づいて約20〜 1000mg/m2であることを特徴とする請求項28に記載の方法。 35.前記有効量が約50〜200mg/m2であることを特徴とする請求項3 4に記載の方法。 36.サイクロスポリンAないしZ、(Me−lle−4)−サイクロスポリン 、ジヒドロサイクロスポリンA、ジヒドロサイクロスポリンC及びアセチルサイ クロスポリンAから成るグループより選ばれた経口生体利用率向上剤の有効量と 共に、前記患者に対して前記タキサンが共投与されることを特徴とする請求項2 7に記載の方法。 37.前記の生体利用率向上剤が、サイクロスポリンA、サイクロスポリンC、 サイクロスポリンD、サイクロスポリンF、ジヒドロサイクロスポリンA、ジヒ ドロサイクロスポリンC及びアセチルサイクロスポリンAから成るグループより 選ばれたものであることを特徴とする請求項36に記載の方法。 38.約0.1〜約20mg/kgの前記向上剤が投与されることを特徴とする 請求項37に記載の方法。 39.約5mg/kgの前記向上剤が投与されることを特徴とする請求項38に 記載の方法。 40.約2〜30mg/kg又は約20〜1000mg/m2のパクリタクセル が、約0.1〜20mg/kgのサイクロスポリンAと共に、前記患者に対して 共投与されることを特徴とする請求項27に記載の方法。 41.前記向上剤が、 a)前記タキサン投与の約0.5〜72時間前、 b)前記タキサン投与の0.5時間以内前、前記タキサン投与と一緒に、 又は前記タキサン投与の0.5時間以内後、又は c)前記タキサン投与の約0.5〜72時間前と、再び、0.5時間以内 前、一緒に、又は0.5時間以内後の両方、 のいずれかで投与されることを特徴とする請求項27に記載の方法。 42.前記タキサンがパクリタクセルであり、しかも前記向上剤がサイクロスポ リンAであることを特徴とする請求項41に記載の方法。 43.前記タキサンと前記向上剤がそれぞれ、個別の経口投薬形態にて投与され ることを特徴とする請求項27に記載の方法。 44.前記タキサンと前記向上剤が、混合型経口投薬形態にて一緒に投与される ことを特徴とする請求項27に記載の方法。 45.前記疾患状態が、癌、腫瘍、悪性腫瘍、組織損傷に二次的な無制御組織ま たは細胞性増殖、多嚢胞性腎臓病及びマラリアから成るグループより選ばれたも のであることを特徴とする請求項10、11、27又は28に記載の方法。 46.前記疾患が、肝細胞性癌、肝臓転移、胃腸管、膵臓、前立腺及び肺の癌、 及びカポージ肉腫から成るグループより選ばれた癌であることを特徴とする請求 項45に記載の方法。 47.タキサン応答性のある疾患状態に対するタキサン療法を受けている人間の 患者における過敏症及びアレルギー性反応を防止又は減少させるための方法であ って、前記方法が、前記患者に対してタキサンを経口投与することを含むことを 特徴とする、タキサン応答性のある疾患状態に対するタキサン療法を受けている 人間の患者における過敏症及びアレルギー性反応を防止又は減少させる方法。 48.前記タキサンがパクリタクセルであることを特徴とする請求項47に記載 の方法。 49.前記タキサンがドセタクセルであることを特徴とする請求項47に記載の 方法。 50.前記タキサンが、パクリタクセル又はドセタクセルの誘導体、類似物又は プロドラッグであることを特徴とする請求項47に記載の方法。 51.前記タキサンが、プロドラッグであるパクリタクセル−2’−MPM又は プロドラッグであるドセタクセル−2’−MPMであることを特徴とする請求項 50に記載の方法。 52.前記タキサンが、過敏症又はタキサンに対するアレルギー性反応を防止す るために、投薬の事前投与を行わずに前記患者に投与されることを特徴とする請 求項47に記載の方法。 53.前記タキサンが、サイクロスポリンAないしZ、(Me−lle−4)− サイクロスポリン、ジヒドロサイクロスポリンA、ジヒドロサイクロスポリンC 及びアセチルサイクロスポリンAから成るグループより選ばれた経口生体利用率 向上剤の有効量と共に、経口的に共投与されることを特徴とする請求項47に記 載の方法。 54.前記の生体利用率向上剤が、サイクロスポリンA、サイクロスポリンC、 サイクロスポリンD、サイクロスポリンF、ジヒドロサイクロスポリンA、ジヒ ドロサイクロスポリンC及びアセチルサイクロスポリンAから成るグループより 選ばれたものであることを特徴とする請求項53に記載の方法。 55.前記の生体利用率向上剤がサイクロスポリンAであることを特徴とする請 求項54に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86351397A | 1997-05-27 | 1997-05-27 | |
US08/863,513 | 1997-05-27 | ||
PCT/US1998/007776 WO1998053811A1 (en) | 1997-05-27 | 1998-04-22 | Method and compositions for administering taxanes orally to human patients |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2002500667A true JP2002500667A (ja) | 2002-01-08 |
Family
ID=25341241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50066399A Pending JP2002500667A (ja) | 1997-05-27 | 1998-04-22 | 人間の患者に対して経口的にタキサン類を投薬するための方法及び組成物 |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP0994706B1 (ja) |
JP (1) | JP2002500667A (ja) |
KR (1) | KR100615783B1 (ja) |
CN (2) | CN1550231A (ja) |
AR (1) | AR012731A1 (ja) |
AT (1) | ATE308365T1 (ja) |
AU (1) | AU7130098A (ja) |
BR (1) | BR9809694A (ja) |
CA (1) | CA2290446C (ja) |
CZ (1) | CZ9904244A3 (ja) |
DE (1) | DE69832173T2 (ja) |
DK (1) | DK0994706T3 (ja) |
ES (1) | ES2247690T3 (ja) |
HK (1) | HK1026637A1 (ja) |
HU (1) | HUP0003546A3 (ja) |
IL (2) | IL132992A0 (ja) |
NO (1) | NO995812L (ja) |
PL (1) | PL337064A1 (ja) |
RU (1) | RU2205005C2 (ja) |
SK (1) | SK157599A3 (ja) |
UA (1) | UA74767C2 (ja) |
WO (1) | WO1998053811A1 (ja) |
ZA (1) | ZA984268B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012528875A (ja) * | 2009-06-02 | 2012-11-15 | ナイカン ファーマシューティカルズ, エルエルシー | 疾患の処置のためのヒトホルミルペプチド受容体の拮抗作用 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
CA2294606A1 (en) * | 1997-06-20 | 1998-12-30 | Baker Norton Pharmaceuticals, Inc. | Soluble prodrugs of paclitaxel |
GB9718903D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
DE60030283T2 (de) | 1999-05-17 | 2007-09-20 | Cancer Research Ventures Ltd. | Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen |
SK5822002A3 (en) * | 1999-10-27 | 2003-01-09 | Baker Norton Pharma | Method and compositions for administering taxanes orally to human patients |
KR20020013174A (ko) * | 2000-08-11 | 2002-02-20 | 민경윤 | 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물 |
MXPA03006404A (es) * | 2001-01-18 | 2004-12-02 | Upjohn Co | Composiciones quimioterapeuticas de microemulsion de paclitaxel con biodisponibilidad oral mejorada. |
US7115565B2 (en) | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
UY27185A1 (es) * | 2001-02-28 | 2002-09-30 | Bristol Myers Squibb Co | Dosificación metronómica de taxanos |
SI1372636T1 (sl) * | 2001-02-28 | 2006-12-31 | Bristol Myers Squibb Co | Metronomsko odmerjanje taksanov za inhibiranje tumorske rasti |
US7063977B2 (en) | 2001-08-21 | 2006-06-20 | Bristol-Myers Squibb Company | Enzymatic resolution of t-butyl taxane derivatives |
GB0523659D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
BR112023018826A2 (pt) * | 2021-03-17 | 2024-03-12 | Dompe Farm Spa | Inibidores de c5ar1 para tratamento de reações de hipersensibilidade a taxanos |
EP4059497A1 (en) * | 2021-03-17 | 2022-09-21 | Dompé farmaceutici S.p.a. | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
ATE139447T1 (de) * | 1990-12-18 | 1996-07-15 | Wellcome Found | Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen |
EP0569380B1 (en) * | 1991-01-11 | 1997-05-28 | Laboratoires Glaxo Sa | Acridine derivatives |
US5567592A (en) * | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
ATE176464T1 (de) * | 1994-07-26 | 1999-02-15 | Indena Spa | Semisynthetisch taxal derivate mit antitumor wirkung |
TW354293B (en) * | 1995-06-06 | 1999-03-11 | Bristol Myers Squibb Co | Prodrugs of paclitaxel derivatives |
EP0831870A4 (en) * | 1995-06-07 | 1998-09-16 | Avmax Inc | USE OF ESSENTIAL OILS TO INCREASE THE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS |
US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
WO1997027855A1 (en) * | 1996-01-31 | 1997-08-07 | Bristol-Myers Squibb Company | A method of making pharmaceutically active taxanes orally bioavailable |
AU3486297A (en) * | 1996-06-17 | 1998-01-07 | Eli Lilly And Company | Drug resistance and multidrug resistance modulators |
GB9718903D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
DE69931617T2 (de) * | 1998-04-01 | 2007-05-24 | Jagotec Ag | Taxan-mikroemulsionen |
-
1998
- 1998-04-22 KR KR1019997011000A patent/KR100615783B1/ko not_active IP Right Cessation
- 1998-04-22 CN CNA2004100304785A patent/CN1550231A/zh active Pending
- 1998-04-22 ES ES98918361T patent/ES2247690T3/es not_active Expired - Lifetime
- 1998-04-22 CN CN98806440A patent/CN1261275A/zh active Pending
- 1998-04-22 AT AT98918361T patent/ATE308365T1/de not_active IP Right Cessation
- 1998-04-22 AU AU71300/98A patent/AU7130098A/en not_active Abandoned
- 1998-04-22 BR BR9809694-0A patent/BR9809694A/pt not_active IP Right Cessation
- 1998-04-22 SK SK1575-99A patent/SK157599A3/sk unknown
- 1998-04-22 JP JP50066399A patent/JP2002500667A/ja active Pending
- 1998-04-22 HU HU0003546A patent/HUP0003546A3/hu unknown
- 1998-04-22 CA CA002290446A patent/CA2290446C/en not_active Expired - Fee Related
- 1998-04-22 DK DK98918361T patent/DK0994706T3/da active
- 1998-04-22 PL PL98337064A patent/PL337064A1/xx unknown
- 1998-04-22 RU RU99128033/14A patent/RU2205005C2/ru not_active IP Right Cessation
- 1998-04-22 EP EP98918361A patent/EP0994706B1/en not_active Expired - Lifetime
- 1998-04-22 DE DE69832173T patent/DE69832173T2/de not_active Expired - Fee Related
- 1998-04-22 IL IL13299298A patent/IL132992A0/xx active IP Right Grant
- 1998-04-22 WO PCT/US1998/007776 patent/WO1998053811A1/en active IP Right Grant
- 1998-04-22 UA UA99116450A patent/UA74767C2/uk unknown
- 1998-04-22 CZ CZ19994244A patent/CZ9904244A3/cs unknown
- 1998-05-20 ZA ZA984268A patent/ZA984268B/xx unknown
- 1998-05-21 AR ARP980102356A patent/AR012731A1/es unknown
-
1999
- 1999-11-17 IL IL132992A patent/IL132992A/en not_active IP Right Cessation
- 1999-11-26 NO NO995812A patent/NO995812L/no not_active Application Discontinuation
-
2000
- 2000-09-20 HK HK00105943A patent/HK1026637A1/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012528875A (ja) * | 2009-06-02 | 2012-11-15 | ナイカン ファーマシューティカルズ, エルエルシー | 疾患の処置のためのヒトホルミルペプチド受容体の拮抗作用 |
Also Published As
Publication number | Publication date |
---|---|
DE69832173T2 (de) | 2006-08-03 |
CZ9904244A3 (cs) | 2001-10-17 |
ATE308365T1 (de) | 2005-11-15 |
HK1026637A1 (en) | 2000-12-22 |
EP0994706A4 (en) | 2001-05-16 |
WO1998053811A1 (en) | 1998-12-03 |
EP0994706A1 (en) | 2000-04-26 |
ES2247690T3 (es) | 2006-03-01 |
EP0994706B1 (en) | 2005-11-02 |
CN1550231A (zh) | 2004-12-01 |
NO995812L (no) | 2000-01-25 |
SK157599A3 (en) | 2002-10-08 |
IL132992A (en) | 2006-08-20 |
CA2290446C (en) | 2008-01-29 |
ZA984268B (en) | 1999-06-23 |
KR20010013025A (ko) | 2001-02-26 |
AR012731A1 (es) | 2000-11-08 |
CA2290446A1 (en) | 1998-12-03 |
UA74767C2 (en) | 2006-02-15 |
BR9809694A (pt) | 2000-10-03 |
HUP0003546A2 (hu) | 2002-11-28 |
NO995812D0 (no) | 1999-11-26 |
AU7130098A (en) | 1998-12-30 |
CN1261275A (zh) | 2000-07-26 |
HUP0003546A3 (en) | 2002-12-28 |
DK0994706T3 (da) | 2006-03-06 |
PL337064A1 (en) | 2000-07-31 |
KR100615783B1 (ko) | 2006-08-25 |
IL132992A0 (en) | 2001-03-19 |
RU2205005C2 (ru) | 2003-05-27 |
DE69832173D1 (de) | 2005-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3361102B2 (ja) | 医薬の経口生体利用率を増加させるための方法、組成物およびキット | |
US6395770B1 (en) | Method and compositions for administering taxanes orally to human patients | |
US6964946B1 (en) | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same | |
JP2002500667A (ja) | 人間の患者に対して経口的にタキサン類を投薬するための方法及び組成物 | |
KR20030019296A (ko) | 인체 환자에게 탁산을 경구 투여하는 방법 및 조성물 | |
AU784159B2 (en) | Method and compositions for administering taxanes orally to human patients | |
EP1634607A2 (en) | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents | |
KR100563824B1 (ko) | 제약학적약물의경구생체내이용효율을증가시키기위한조성물및키트 | |
MXPA99010850A (en) | Method and compositions for administering taxanes orally to human patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20040331 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060627 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20060704 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060925 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061215 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20061215 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081209 |